The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of androgen deprivation, darolutamide, and ipatasertib in a safety cohort with castration-resistant prostate cancer (ADDITION).
 
Sarah Elizabeth Fenton
No Relationships to Disclose
 
Rachel Springsdorf
No Relationships to Disclose
 
Siobhan Kenny
No Relationships to Disclose
 
Lauren Bere
No Relationships to Disclose
 
Ashley Ross
Honoraria - Astellas Pharma; Bayer; Blue Earth Diagnostics; Decipher Biosciences; Janssen Biotech; Lantheus Medical Imaging; Myovant Sciences; tempus
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Tempus
 
Masha Kocherginsky
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; AstraZeneca; AstraZeneca; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Precisca; Targeted Oncology; UroToday
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Pfizer; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
David James VanderWeele
Honoraria - Astellas Pharma
Consulting or Advisory Role - Bayer; Clovis Oncology; Exelixis; Janssen
Research Funding - AstraZeneca (Inst); Department of Defense-Prostate Cancer Research Program; Fortis (Inst); Prostate Cancer Foundation